

Figure S1. TTC22V1 expression changes in xenografts from HCT116 cells with stable *miR663a* upregulation determined using western blot analysis. TTC22V1, tetratricopeptide repeat domain 22 variant 1; *miR663a*, microRNA-663a; Ctrl, control.




Figure S2. Effects of *miR663a* expression changes on its target gene expression in HCT116 cells. (A) Cells transiently transfected with the pri-miR663a expression vector and pcDNA3.1 control vector. (B) Cells transiently transfected with an antisense/inhibitor and scrambled RNA control. *miR663a*, microRNA-663a; pri-, primary transcript; Ctrl, control.




Figure S3. Localization of the endogenous TTC22V1 protein in different colon cancer cells according to immunofluorescence confocal microscope examination. TTC22V1, tetratricopeptide repeat domain 22 variant 1; IgG, immunoglobulin G.




Figure S4. Kaplan-Meier survival curves and other information for patients with colon carcinoma expressing high and low levels of TTC22 reported previously. (A) TCGA-COAD dataset (30). (B) Loboda Yeatman dataset (31). (C) Sveen colon dataset (32). The images were downloaded from bioinformatica.mty.itesm.mx:8080/Biomatec/SurvivaX.jsp (maximized risk group mode). TCGA-COAD, The Cancer Genome Atlas-Colon Adenocarcinoma.

